Danaher Q1 2026 Earnings Beat, Lifts Outlook

Danaher Corporation (DHR) reported adjusted EPS that topped expectations on April 21, 2026, prompting management to raise its full-year adjusted EPS outlook and announce plans to acquire Masimo.

Quarter Results, Guidance, and Segment Performance

Danaher posted non-GAAP adjusted diluted EPS of $2.06, up 9.5% year-over-year and 5.9% above the $1.95 consensus, on revenue of $5.95 billion, a 3.5% increase that fell short of the $5.99 billion estimate. Non-GAAP core revenue grew 0.5% year-over-year, or about 3% excluding a respiratory-diagnostics headwind. The company raised its full-year non-GAAP adjusted diluted EPS guidance to $8.35–$8.55 and reaffirmed core revenue growth of 3%–6%. It expects second-quarter core revenue to rise in the low single digits with an adjusted operating profit margin near 26.5%.

Bioprocessing and Life Sciences segments showed double-digit momentum, offsetting weakness in Diagnostics, which reflected a lighter-than-typical respiratory season at Cepheid. On a GAAP basis, net earnings ranged from $1.0 billion to $1.03 billion, with diluted EPS of $1.45, up from $1.32. Operating cash flow was between $1.3 billion and $1.322 billion, and non-GAAP free cash flow totaled $1.1 billion.

Danaher announced its intention to acquire Masimo and secured a new $5.0 billion credit facility to support growth initiatives. President and Chief Executive Officer Rainer M. Blair said, "Our team executed well in the first quarter," citing strong execution that enabled nearly 10% adjusted EPS growth driven by innovation and productivity gains. He noted that strength in Bioprocessing and better-than-expected Life Sciences performance largely offset the impact of the weaker respiratory season at Cepheid.